Wave Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $13.17.
A number of research firms have issued reports on WVE. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Wave Life Sciences in a research note on Wednesday, June 26th. StockNews.com lowered Wave Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Mizuho reiterated an “outperform” rating and set a $19.00 price target on shares of Wave Life Sciences in a research report on Tuesday, June 25th. Finally, Wells Fargo & Company began coverage on Wave Life Sciences in a report on Wednesday, May 15th. They set an “overweight” rating and a $11.00 price target on the stock.
Get Our Latest Stock Analysis on Wave Life Sciences
Institutional Investors Weigh In On Wave Life Sciences
Wave Life Sciences Stock Performance
Shares of WVE stock opened at $5.83 on Thursday. The stock has a market capitalization of $714.03 million, a price-to-earnings ratio of -11.21 and a beta of -1.12. Wave Life Sciences has a one year low of $3.50 and a one year high of $7.67. The company’s 50-day simple moving average is $5.75 and its 200-day simple moving average is $5.58.
Wave Life Sciences (NASDAQ:WVE – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.09). Wave Life Sciences had a negative return on equity of 1,395.99% and a negative net margin of 66.50%. The firm had revenue of $19.69 million for the quarter, compared to the consensus estimate of $24.80 million. During the same period in the prior year, the business earned ($0.20) EPS. As a group, research analysts forecast that Wave Life Sciences will post -1.05 EPS for the current year.
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
See Also
- Five stocks we like better than Wave Life Sciences
- What is a Special Dividend?
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- How to Find Undervalued Stocks
- 2 Option Strategies to Maximize Profits in a Bear Market
- Airline Stocks – Top Airline Stocks to Buy Now
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.